Buy Orciprenaline Sulphate powder (5874-97-5) hplc≥98% – Wisepowder
Name Orciprenaline sulphate powder
Chemical name 3-hydroxy-5-(1-hydroxy-2-(isopropylamino)ethyl)phenyl hydrogen sulfate
Synonyms Th-152; Th 152; Th152; Metaprel; Metaproterenol;Metaproterenol Polistirex; Alotec; Alupent; Astmopent; Orciprenaline; Metaproterenol sulfate; Metaproterenol Hemisulfate
Molecular Formula C22H36N2O10S
Molecular Weight 520.594 g/mol
Melting Point 202-203°C
InChI Key MKFFGUZYVNDHIH-UHFFFAOYSA-N
Appearance White to Off-White
Half Life 3 to 6 hours
Solubility Freely soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.
Storage Condition Hygroscopic, -20°C Freezer, Under inert atmosphere
Application Orciprenaline sulphate is a bronchodilating agent.
Testing Document Available\
03 Orciprenaline Sulphate powder General Description
Orciprenaline, also known as metaproterenol, is a bronchodilator used inthe treatment of asthma. Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects ofβ adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular adenylyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.
Orciprenaline sulphate has the following major characteristics: The action of Orciprenaline sulphate is one of beta stimulation. Receptor sites inthe bronchiand bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favorable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely tocause cardiovascular side effects.
04 Orciprenaline Sulphate powder History
Orciprenaline sulphate powder , a non-specific β-agonist, was formerly licensed for reversible airway obstruction and suggested for maintenance therapy. The Medicines and Healthcare products Regulatory Agency (MHRA) is thegovernment agency responsible for regulating the effectiveness and safetyof medicines and medical devices in the UK. This MHRA Public Assessment Report discusses a review of the risks and benefits of orciprenaline sulphate. The non-selective β-agonist1 orciprenaline sulphate also known as metaproterenol sulphate was originally developed from isoprenaline.Orciprenaline sulphate is the active ingredient of Alupent syrup (10 mg/5 mL), which was registered in the UK in September 1972 and is currently indicated for the relief of reversible airways obstruction and suggested for maintenance therapy. It is to be withdrawn from the UK market on 30 September 2010.